Medi-Cal serves more than one-third of the state’s population — offering a dizzying range of care to a diverse population. In the new “Faces of Medi-Cal” series, California Healthline will assess the program’s strengths and weaknesses through the lives and experiences of its enrollees.
When Medicare stops paying for a pricey drug that prolongs life, an Ohio man considers giving up treatment to spare his family enormous debt.
The proportion of Californians dying at home, rather than in a hospital or nursing home, accelerated during the pandemic, a trend that has outlasted the rigid lockdowns linked to the initial shift.
When Penelope Wingard’s cancer went into remission, she lost her Medicaid coverage in North Carolina. Without insurance, the debts piled up for her follow-up care. She doesn’t think she’ll ever get ahead of it.
Monica Reed was the first in her family to own a home and has lived “a frugal kind of life.” Cancer treatment left her with almost $10,000 in debt, pushing her to the edge financially.
Improving lung cancer outcomes in Black communities will take more than lowering the screening age, experts say. Disparities are present in everything from the studies that inform when people should get checked to the availability of care in rural areas.
When Katie Couric announced she had breast cancer, she urged women to get a mammogram — and, if they have dense breasts, to get supplemental screening by ultrasound. But medical experts point out that ultrasound and other auxiliary screenings haven’t been proven to do more than regular mammography in reducing mortality.
Lupron, a drug patented half a century ago, treats advanced prostate cancer. It’s sold to physicians for $260 in the U.K. and administered at no charge. Why are U.S. hospitals — which may pay nearly as little for the drug — charging so much more to administer it?
Creole-speaking public health workers teach women how to test themselves for HPV, the virus that causes some cervical cancers.
As abortion restrictions take effect across the South in the wake of the Supreme Court’s decision to overturn Roe v. Wade, cancer doctors are trying to decipher the laws. They’re grappling with how to discuss options with pregnant patients, who may be forced to choose whether to proceed or forgo lifesaving cancer treatments that can prove toxic for the fetus.
